Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2800) 2800
Publication (221) 221
Book Review (167) 167
Book Chapter (25) 25
Conference Proceeding (4) 4
Book / eBook (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2718) 2718
animals (1783) 1783
humans (1377) 1377
oligodeoxyribonucleotides, antisense - pharmacology (1314) 1314
base sequence (820) 820
mice (774) 774
rats (656) 656
male (619) 619
molecular sequence data (573) 573
biochemistry & molecular biology (564) 564
oligodeoxyribonucleotides - pharmacology (537) 537
expression (446) 446
female (445) 445
cells, cultured (433) 433
rna, messenger - genetics (370) 370
transfection (366) 366
pharmacology & pharmacy (343) 343
tumor cells, cultured (318) 318
oligodeoxyribonucleotides, antisense - genetics (317) 317
cell line (310) 310
oligodeoxyribonucleotides (310) 310
neurosciences (294) 294
oligonucleotides (286) 286
rna, messenger - metabolism (284) 284
cells (272) 272
rats, sprague-dawley (269) 269
cell biology (262) 262
oligodeoxynucleotides (248) 248
oligonucleotides, antisense - pharmacology (244) 244
gene-expression (241) 241
apoptosis (238) 238
oncology (231) 231
antisense oligonucleotides (227) 227
dna (226) 226
cell division - drug effects (216) 216
cell line, tumor (216) 216
research (216) 216
inhibition (215) 215
oligodeoxyribonucleotides - chemistry (213) 213
activation (209) 209
kinetics (207) 207
dose-response relationship, drug (204) 204
immunology (193) 193
in-vivo (192) 192
medicine, research & experimental (192) 192
antisense (187) 187
gene expression (187) 187
thionucleotides - pharmacology (187) 187
apoptosis - drug effects (186) 186
messenger-rna (186) 186
rna (180) 180
multidisciplinary sciences (178) 178
gene expression regulation - drug effects (172) 172
proteins (171) 171
time factors (157) 157
mice, inbred balb c (145) 145
signal transduction (144) 144
amino acid sequence (143) 143
in-vitro (141) 141
reverse transcriptase polymerase chain reaction (141) 141
biotechnology & applied microbiology (139) 139
gene (137) 137
rna, messenger - biosynthesis (136) 136
abridged index medicus (135) 135
cancer (135) 135
oligodeoxyribonucleotides, antisense - therapeutic use (134) 134
oligodeoxyribonucleotides, antisense - administration & dosage (130) 130
physiological aspects (130) 130
bacterial-dna (129) 129
enzyme inhibitors - pharmacology (129) 129
phosphorylation (128) 128
polymerase chain reaction (127) 127
gene expression - drug effects (125) 125
protein (125) 125
genes (120) 120
disease models, animal (117) 117
mice, inbred c57bl (117) 117
analysis (115) 115
oligodeoxyribonucleotides, antisense (113) 113
article (112) 112
antineoplastic agents - pharmacology (111) 111
transcription, genetic - drug effects (109) 109
cell proliferation - drug effects (108) 108
rats, wistar (107) 107
nucleic acid conformation (106) 106
oligodeoxyribonucleotides - metabolism (105) 105
hematology (102) 102
cloning, molecular (101) 101
messenger rna (101) 101
down-regulation (99) 99
in vitro techniques (99) 99
oligodeoxyribonucleotides - administration & dosage (99) 99
transcription, genetic (98) 98
oligodeoxyribonucleotides - genetics (94) 94
oligodeoxyribonucleotides, antisense - chemistry (93) 93
cell survival - drug effects (92) 92
genetic aspects (92) 92
receptor (91) 91
proliferation (90) 90
binding (89) 89
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2665) 2665
Chinese (127) 127
Japanese (5) 5
Russian (3) 3
German (2) 2
Polish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
by Geary, Richard S and Baker, Brenda F and Crooke, Stanley T
Clinical Pharmacokinetics, ISSN 0312-5963, 2/2015, Volume 54, Issue 2, pp. 133 - 146
Mipomersen (Kynamro®), a second-generation 2′-O-methoxyethyl chimeric antisense oligonucleotide (ASO), inhibits the synthesis of apolipoprotein B (apoB) and is... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LDL CHOLESTEROL | DENSITY-LIPOPROTEIN CHOLESTEROL | IN-VITRO | METAANALYSIS | EFFICACY | REDUCTION | HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | CARDIOVASCULAR RISK | Apolipoproteins B - antagonists & inhibitors | Oligonucleotides - chemistry | Oligodeoxyribonucleotides, Antisense - pharmacology | Humans | Models, Molecular | Anticholesteremic Agents - chemistry | Clinical Trials as Topic | Oligonucleotides - pharmacokinetics | Anticholesteremic Agents - pharmacokinetics | Animals | Oligonucleotides - pharmacology | Base Sequence | Hyperlipoproteinemia Type I - drug therapy | Hyperlipoproteinemia Type I - metabolism | Anticholesteremic Agents - pharmacology | Oligodeoxyribonucleotides, Antisense - pharmacokinetics | Care and treatment | Hypercholesterolemia | Analysis | Mipomersen | Dosage and administration | Pharmacology | Pharmacokinetics | Index Medicus | Review
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Pharmacology of a central nervous system delivered 2′-O-methoxyethyl- modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates
by Rigo, Frank and Chun, Seung J and Norris, Daniel A and Hung, Gene and Lee, Sam and Matson, John and Fey, Robert A and Gaus, Hans and Hua, Yimin and Grundy, John S and Krainer, Adrian R and Henry, Scott P and Bennett, C. Frank
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 2014, Volume 350, Issue 1, pp. 46 - 55
Spinal muscular atrophy (SMA) is a debilitating neuromuscular disease caused by the loss of survival of motor neuron (SMN) protein. Previously, we demonstrated... 
SEVERE MOUSE MODEL | EXON | GENE SMN2 | SPINAL MUSCULAR-ATROPHY | RNA | LOCKED NUCLEIC-ACID | IN-VIVO | PHARMACOLOGY & PHARMACY | ANTISENSE OLIGONUCLEOTIDES | SINGLE NUCLEOTIDE | TRANSGENIC MICE | RNA Splicing - drug effects | Oligodeoxyribonucleotides, Antisense - pharmacology | Oligodeoxyribonucleotides, Antisense - administration & dosage | Oligonucleotides - therapeutic use | Injections, Intraventricular | Macaca fascicularis | Oligodeoxyribonucleotides, Antisense - therapeutic use | Male | Oligonucleotides - pharmacokinetics | Mice, Knockout | Brain - drug effects | Brain - metabolism | Muscular Atrophy, Spinal - genetics | Animals | Oligonucleotides - pharmacology | Survival of Motor Neuron 2 Protein - genetics | Female | Muscular Atrophy, Spinal - drug therapy | Mice | Oligonucleotides - administration & dosage | Infusions, Intraventricular | Oligodeoxyribonucleotides, Antisense - pharmacokinetics | Index Medicus | Drug Discovery and Translational Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates
by Lindholm, Marie W and Elmén, Joacim and Fisker, Niels and Hansen, Henrik F and Persson, Robert and Møller, Marianne R and Rosenbohm, Christoph and Ørum, Henrik and Straarup, Ellen M and Koch, Troels
Molecular Therapy, ISSN 1525-0016, 02/2012, Volume 20, Issue 2, pp. 376 - 381
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for the reduction of low-density lipoprotein cholesterol (LDL-C).... 
MEDICINE, RESEARCH & EXPERIMENTAL | DOMAIN | SERUM-CHOLESTEROL | ANTIBODY | HYPERCHOLESTEROLEMIA | METABOLISM | GENE | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | GENETICS & HEREDITY | MICE | MUTATIONS | SPECTRUM | BINDING | Proprotein Convertases - antagonists & inhibitors | Oligonucleotides - chemistry | Oligodeoxyribonucleotides, Antisense - pharmacology | Oligodeoxyribonucleotides, Antisense - administration & dosage | Humans | Proprotein Convertases - metabolism | Macaca fascicularis | Male | Proprotein Convertases - genetics | Animals | Injections, Subcutaneous | Serine Endopeptidases - genetics | Cholesterol, LDL - metabolism | Serine Endopeptidases - metabolism | Proprotein Convertase 9 | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Antisense inhibition of survivin expression as a cancer therapeutic
by Carrasco, Rosa A and Stamm, Nancy B and Marcusson, Eric and Sandusky, George and Iversen, Philip and Patel, Bharvin K. R
Molecular Cancer Therapeutics, ISSN 1535-7163, 02/2011, Volume 10, Issue 2, pp. 221 - 232
Survivin, a family member of the inhibitor of apoptosis proteins that is expressed during mitosis in a cell cycle-dependent manner and localized to different... 
ANTI-APOPTOSIS GENE | ONCOLOGY | COLORECTAL-CANCER | CRYSTAL-STRUCTURE | PROTEIN SURVIVIN | IN-VIVO | GROWTH | TARGETING SURVIVIN | PROGNOSTIC VALUE | OVARIAN-CARCINOMA | CELL-DEATH | Neoplasms - metabolism | Oligodeoxyribonucleotides, Antisense - pharmacology | Apoptosis - drug effects | Inhibitor of Apoptosis Proteins - genetics | HCT116 Cells | Humans | Caspase 3 - metabolism | Down-Regulation - drug effects | Cell Division - drug effects | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Inhibitor of Apoptosis Proteins - metabolism | Mice | Gene Expression Regulation, Neoplastic - drug effects | HeLa Cells | Neoplasms - physiopathology | Cell Cycle - drug effects | Antisense oligonucleotides | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
by Goyenvalle, Aurélie and Griffith, Graziella and Babbs, Arran and Andaloussi, Samir El and Ezzat, Kariem and Avril, Aurélie and Dugovic, Branislav and Chaussenot, Rémi and Ferry, Arnaud and Voit, Thomas and Amthor, Helge and Bühr, Claudia and Schürch, Stefan and Wood, Matthew J A and Davies, Kay E and Vaillend, Cyrille and Leumann, Christian and Garcia, Luis
Nature Medicine, ISSN 1078-8956, 2015, Volume 21, Issue 3, pp. 270 - 275
Antisense oligonucleotides (AONs) hold promise for therapeutic correction of many genetic diseases via exon skipping, and the first AON-based drugs have... 
MEDICINE, RESEARCH & EXPERIMENTAL | MDX MOUSE | UTROPHIN | BIOCHEMISTRY & MOLECULAR BIOLOGY | CARDIOMYOPATHY | DEFICIENT MICE | OLIGONUCLEOTIDES | IMPAIRMENT | CELL BIOLOGY | GENE | 2'-O-METHYL PHOSPHOROTHIOATE | SKELETAL | EXPRESSION | Genetic Therapy | Microscopy, Electron, Transmission | Oligodeoxyribonucleotides, Antisense - pharmacology | Exons | RNA, Messenger - analysis | Muscle, Skeletal - metabolism | Transcriptome - drug effects | Codon, Nonsense | Blood-Brain Barrier - metabolism | Nanoparticles | Animals | Dystrophin - genetics | Muscle, Skeletal - drug effects | Myocardium - metabolism | Heart - drug effects | Mice | Muscular Dystrophy, Duchenne | Dystrophin - drug effects | Disease Models, Animal | Oligodeoxyribonucleotides, Antisense - metabolism | Antisense drugs | Exon (Molecular genetics) | Genetic aspects | Dosage and administration | Drug therapy | Health aspects | Muscular dystrophy | Models | Neurons | Rodents | Deoxyribonucleic acid--DNA | Index Medicus | Heart | Neurons and Cognition | Psychology and behavior | Transcriptome | Neurobiology | Life Sciences | Myocardium | Cognitive Sciences | Muscle, Skeletal | Oligodeoxyribonucleotides, Antisense | RNA, Messenger | Dystrophin | Blood-Brain Barrier
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models
by Zhao, Hien Tran and Damle, Sagar and Ikeda-Lee, Karli and Kuntz, Steven and Li, Jian and Mohan, Apoorva and Kim, Aneeza and Hung, Gene and Scheideler, Mark A and Scherer, Steven S and Svaren, John and Swayze, Eric E and Kordasiewicz, Holly B
Journal of Clinical Investigation, ISSN 0021-9738, 01/2018, Volume 128, Issue 1, pp. 359 - 368
Charcot-Marie-Tooth disease type 1A (CMT1A) is caused by duplication of peripheral myelin protein 22 (PMP22) and is the most common hereditary peripheral... 
PERIPHERAL-NERVE | MEDICINE, RESEARCH & EXPERIMENTAL | TRANSGENIC RAT MODEL | MYELIN | AXONAL LOSS | GENE | ASCORBIC-ACID TREATMENT | MOUSE MODEL | MICE | SCHWANN-CELLS | EXPRESSION | Action Potentials - genetics | Oligodeoxyribonucleotides, Antisense - pharmacology | Skin - metabolism | Myelin Proteins - antagonists & inhibitors | RNA, Messenger - genetics | Myelin Proteins - biosynthesis | Male | Mice, Transgenic | Charcot-Marie-Tooth Disease - drug therapy | Charcot-Marie-Tooth Disease - pathology | Myelin Proteins - genetics | Motor Neurons - pathology | Charcot-Marie-Tooth Disease - genetics | Motor Neurons - metabolism | RNA, Messenger - biosynthesis | Animals | RNA, Messenger - antagonists & inhibitors | Female | Mice | Charcot-Marie-Tooth Disease - metabolism | Action Potentials - drug effects | Skin - pathology | Disease Models, Animal | RNA | Gene expression | Charcot-Marie-Tooth disease | Analysis | Genes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Antimicrobial activity of antisense peptide-peptide nucleic acid conjugates against non-typeable Haemophilus influenzae in planktonic and biofilm forms
by Otsuka, Taketo and Brauer, Aimee L and Kirkham, Charmaine and Sully, Erin K and Pettigrew, Melinda M and Kong, Yong and Geller, Bruce L and Murphy, Timothy F
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 2017, Volume 72, Issue 1, pp. 137 - 144
Background: Antisense peptide nucleic acids (PNAs) are synthetic polymers that mimic DNA/RNA and inhibit bacterial gene expression in a sequence-specific... 
INFECTIOUS DISEASES | RESPIRATORY-TRACT | ENTERICA SEROVAR TYPHIMURIUM | ESCHERICHIA-COLI | TISSUE-CULTURE | MICROBIOLOGY | BACTERIAL BIOFILMS | IN-VITRO | PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER | ACUTE OTITIS-MEDIA | GENE-EXPRESSION | PHARMACOLOGY & PHARMACY | MIDDLE-EAR | Biofilms - drug effects | Microbial Sensitivity Tests | Peptide Nucleic Acids - pharmacology | Bacterial Proteins - antagonists & inhibitors | Oligodeoxyribonucleotides, Antisense - pharmacology | Haemophilus influenzae - drug effects | Haemophilus influenzae - physiology | Drug Resistance, Bacterial | Acyl Carrier Protein - antagonists & inhibitors | Anti-Bacterial Agents - pharmacology | Serial Passage | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text No effect on QT intervals of mipomersen, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects
by Yu, Rosie Z and Gunawan, Rudy and Li, Zhaoyang and Mittleman, Robert S and Mahmood, Asif and Grundy, John S and Singleton, Walter and Geary, Richard and Wang, Yanfeng
European Journal of Clinical Pharmacology, ISSN 0031-6970, 3/2016, Volume 72, Issue 3, pp. 267 - 275
The aim of this study to evaluate the effect of mipomersen on QT intervals in a phase I dose escalation, placebo-controlled study, and a thorough QT (tQT)... 
Phase I study | Mipomersen | Biomedicine | Pharmacology/Toxicology | Antisense oligonucleotide | tQT | QT | PHARMACOKINETICS | CHOLESTEROL | EFFICACY | SAFETY | PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDE | PHARMACOLOGY & PHARMACY | APOLIPOPROTEIN-B | INHIBITOR | Oligodeoxyribonucleotides, Antisense - blood | Oligodeoxyribonucleotides, Antisense - pharmacology | Double-Blind Method | Humans | Middle Aged | Electrocardiography - drug effects | Male | Apolipoprotein B-100 - genetics | Healthy Volunteers | Oligonucleotides - pharmacokinetics | Cross-Over Studies | Young Adult | Oligonucleotides - pharmacology | Adult | Female | Oligonucleotides - blood | RNA, Messenger | Oligodeoxyribonucleotides, Antisense - pharmacokinetics | Plasma physics | Messenger RNA | Research | Analysis | Heart | Clinical trials | Pharmacology | Clinical outcomes | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text C5-Amino acid functionalized LNA: Positively poised for antisense applications
by Guenther, Dale C and Kumar, Pawan and Anderson, Brooke A and Hrdlicka, Patrick J
Chemical Communications, ISSN 1359-7345, 08/2014, Volume 50, Issue 64, pp. 9007 - 9009
Incorporation of positively charged CS-amino acid functionalized LNA uridines into oligodeoxyribonucleotides (ONs) results in extraordinary RNA affinity,... 
THERMAL-STABILITY | BIOPHYSICAL PROPERTIES | OLIGODEOXYNUCLEOTIDES | MODIFIED OLIGONUCLEOTIDES | LOCKED NUCLEIC-ACID | DNA | HYBRIDIZATION | DUPLEX | OLIGODEOXYRIBONUCLEOTIDES | CHEMISTRY, MULTIDISCIPLINARY | CELLULAR UPTAKE | Oligonucleotides - chemistry | Oligodeoxyribonucleotides, Antisense - pharmacology | Amino Acids - chemistry | 3T3-L1 Cells | RNA - chemistry | Phosphodiesterase I - chemistry | Uridine - pharmacology | RNA - genetics | Exonucleases - chemistry | Animals | Oligonucleotides - pharmacology | Luciferases, Firefly - genetics | Mice | Oligodeoxyribonucleotides, Antisense - chemistry | Uridine - chemistry | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Antisense-Mediated Depletion Reveals Essential and Specific Functions of MicroRNAs in Drosophila Development
by Leaman, Dan and Chen, Po Yu and Fak, John and Yalcin, Abdullah and Pearce, Michael and Unnerstall, Ulrich and Marks, Debora S and Sander, Chris and Tuschl, Thomas and Gaul, Ulrike
Cell, ISSN 0092-8674, 2005, Volume 121, Issue 7, pp. 1097 - 1108
MicroRNAs are small noncoding RNAs that control gene function posttranscriptionally through mRNA degradation or translational inhibition. Much has been learned... 
PROGRAMMED CELL-DEATH | ENCODES | TARGET | ACTIVATION | CAENORHABDITIS-ELEGANS | STRIPES | COMPUTATIONAL IDENTIFICATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | GENE-EXPRESSION | C-ELEGANS | MELANOGASTER | CELL BIOLOGY | Body Patterning - drug effects | Drosophila melanogaster - embryology | MicroRNAs - antagonists & inhibitors | Oligodeoxyribonucleotides, Antisense - pharmacology | Embryo, Nonmammalian - metabolism | Embryonic Development - genetics | Gene Expression Regulation, Developmental - drug effects | Cell Survival - genetics | Gene Expression Regulation, Developmental - genetics | Repressor Proteins - genetics | Apoptosis - genetics | Embryo, Nonmammalian - embryology | Down-Regulation - drug effects | Drosophila melanogaster - genetics | Down-Regulation - genetics | Drosophila melanogaster - metabolism | Animals | RNA Processing, Post-Transcriptional - genetics | MicroRNAs - genetics | Drosophila Proteins - genetics | Neuropeptides - genetics | Embryonic Development - drug effects | Body Patterning - genetics | Repressor Proteins - metabolism | Genetic research | Genetic aspects | Nucleotides | Research | Antisense DNA | Drosophila | Analysis | Messenger RNA | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2
by Zanardi, Thomas A and Han, Su-Cheol and Jeong, Eun Ju and Rime, Soyub and Yu, Rosie Z and Chakravarty, Kaushik and Henry, Scott P
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 11/2012, Volume 343, Issue 2, pp. 489 - 496
ISIS 388626, a 2'-methoxyethyl (MOE)-modified antisense oligonucleotide (ASO) that targets human sodium glucose cotransporter 2 (SGLT2) mRNA, is in clinical... 
Area Under Curve | Oligonucleotides, Antisense - toxicity | Half-Life | Macaca fascicularis | Male | Dose-Response Relationship, Drug | RNA, Messenger - biosynthesis | Kidney - metabolism | Injections, Subcutaneous | Female | Kidney - drug effects | Oligonucleotides, Antisense - pharmacology | Oligonucleotides, Antisense - pharmacokinetics | RNA, Messenger - genetics | Electrocardiography - drug effects | Oligodeoxyribonucleotides - toxicity | Chemistry, Pharmaceutical | Mice, Inbred ICR | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Animals | Oligodeoxyribonucleotides - pharmacokinetics | Hemodynamics - drug effects | Mice | Oligodeoxyribonucleotides - pharmacology | Pharmacokinetics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Potent and Nontoxic Antisense Oligonucleotides Containing Locked Nucleic Acids
by Claes Wahlestedt and Peter Salmi and Liam Good and Johanna Kela and Thomas Johnsson and Tomas Hokfelt and Christian Broberger and Frank Porreca and Josephine Lai and Kunkun Ren and Michael Ossipov and Alexei Koshkin and Nana Jakobsen and Jan Skouv and Henrik Oerum and Mogens Havsteen Jacobsen and Jesper Wengel
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 5/2000, Volume 97, Issue 10, pp. 5633 - 5638
Insufficient efficacy and/or specificity of antisense oligonucleotides limit their in vivo usefulness. We demonstrate here that a high-affinity DNA analog,... 
Biological Sciences | Copolymers | Injections | RNA | Gels | DNA | Oligonucleotides | Antisense oligonucleotides | Nucleic acids | Nucleotides | Monomers | OLIGODEOXYNUCLEOTIDES | MONOMERS | RAT | RECOGNITION | ANALOGS | MULTIDISCIPLINARY SCIENCES | ANTINOCICEPTION | DELTA-OPIOID RECEPTOR | AGONISTS | LNA | ANALGESIA | Oligodeoxyribonucleotides, Antisense - pharmacology | Humans | Rats | Ribonuclease H - drug effects | Breast Neoplasms | Cerebral Ventricles - drug effects | Putamen - drug effects | Stereotaxic Techniques | Cerebral Ventricles - physiology | Thionucleotides | Animals | Biological Transport | Receptors, Opioid, delta - genetics | Base Sequence | Drug Design | Female | Enzyme Activation | Tumor Cells, Cultured | Caudate Nucleus - drug effects | Oligodeoxyribonucleotides, Antisense - chemistry | Oligodeoxyribonucleotides, Antisense - pharmacokinetics | Ribonuclease H - metabolism | Antisense nucleic acids | Research | Deoxyribonucleic acid | Pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Preclinical Characterization of AEG35156/GEM 640, a Second-Generation Antisense Oligonucleotide Targeting X-Linked Inhibitor of Apoptosis
by Eric C. LaCasse and Gabriele G. Cherton-Horvat and Kimberley E. Hewitt and Lori J. Jerome and Stephen J. Morris and Ekambar R. Kandimalla and Dong Yu and Hui Wang and Wei Wang and Ruiwen Zhang and Sudhir Agrawal and John W. Gillard and Jon P. Durkin
Clinical Cancer Research, ISSN 1078-0432, 09/2006, Volume 12, Issue 17, pp. 5231 - 5241
Purpose: Cancer cells can use X-linked inhibitor of apoptosis (XIAP) to evade apoptotic cues, including chemotherapy. The antitumor potential of AEG35156, a... 
XIAP | MBO | preclinical | cancer therapeutic | antisense | LUNG-CANCER | ONCOLOGY | MITOCHONDRIA-DERIVED ACTIVATOR | IAP-FAMILY PROTEINS | PROSTATE-CANCER CELLS | IN-VIVO | XIAP EXPRESSION | GENE-EXPRESSION | DOWN-REGULATION | ACUTE MYELOID-LEUKEMIA | ANTITUMOR-ACTIVITY | Oligodeoxyribonucleotides, Antisense - pharmacology | Apoptosis - drug effects | Humans | Transplantation, Heterologous | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Structure-Activity Relationship | Dose-Response Relationship, Drug | Taxoids - therapeutic use | X-Linked Inhibitor of Apoptosis Protein - antagonists & inhibitors | TNF-Related Apoptosis-Inducing Ligand - pharmacology | Oligonucleotides - pharmacology | Reverse Transcriptase Polymerase Chain Reaction - methods | Sensitivity and Specificity | Antineoplastic Agents - pharmacology | Disease Models, Animal | RNA, Messenger - drug effects | RNA, Messenger - genetics | X-Linked Inhibitor of Apoptosis Protein - genetics | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Mice, Nude | Cell Line, Tumor | Mice | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text PTP1B Antisense Oligonucleotide Lowers PTP1B Protein, Normalizes Blood Glucose, and Improves Insulin Sensitivity in Diabetic Mice
by Bradley A. Zinker and Cristina M. Rondinone and James M. Trevillyan and Rebecca J. Gum and Jill E. Clampit and Jeffrey F. Waring and Nancy Xie and Denise Wilcox and Peer Jacobson and Leigh Frost and Paul E. Kroeger and Regina M. Reilly and Sandra Koterski and Terry J. Opgenorth and Roger G. Ulrich and Seth Crosby and Madeline Butler and Susan F. Murray and Robert A. McKay and Sanjay Bhanot and Brett P. Monia and Michael R. Jirousek
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2002, Volume 99, Issue 17, pp. 11357 - 11362
The role of protein-tyrosine phosphatase 1B (PTP1B) in diabetes was investigated using an antisense oligonucleotide in ob/ob and db/db mice. PTP1B antisense... 
Biological Sciences | Phosphorylation | Messenger RNA | Diabetes complications | Body fat | Liver | Antibodies | Insulin resistance | Mice | Type 2 diabetes mellitus | Insulin | SIGNALING PATHWAYS | ACTIVATION | TYROSINE-PHOSPHATASE 1B | PHOSPHORYLATION | PHOSPHATIDYLINOSITOL 3-KINASE | MULTIDISCIPLINARY SCIENCES | MECHANISMS | PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE | KINASE-B | HEART 6-PHOSPHOFRUCTO-2-KINASE | RECEPTOR SUBSTRATE-1 | Diabetes Mellitus - blood | Insulin - pharmacology | Obesity | Glucose Tolerance Test | Oligodeoxyribonucleotides, Antisense - pharmacology | Diabetes Mellitus - drug therapy | Liver - anatomy & histology | Protein Tyrosine Phosphatases - metabolism | Reference Values | Insulin - blood | Blood Glucose - drug effects | Organ Size - drug effects | Protein Tyrosine Phosphatases - genetics | Animals | RNA, Complementary - genetics | Protein Tyrosine Phosphatase, Non-Receptor Type 1 | Base Sequence | Mice, Obese | Blood Glucose - metabolism | Adipose Tissue - anatomy & histology | Crosses, Genetic | Physiological aspects | Protein research | Diabetes | Analysis | Proteins | Rodents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer
by Zhang, Yixian and Castaneda, Stephen and Dumble, Melissa and Wang, Maoliang and Mileski, Mary and Qu, Zhengxing and Kim, Steven and Shi, Victoria and Kraft, Patricia and Gao, Ying and Pak, Jenny and Sapra, Puja and Bandaru, Raj and Zhao, Hong and Vessella, Robert L and Horak, Ivan D and Greenberger, Lee M
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2011, Volume 10, Issue 12, pp. 2309 - 2319
The androgen receptor (AR) is a member of a unique class of transcription factors because it contains a ligand-binding domain that, when activated, results in... 
RESPONSIVE GENES | LNCAP MODEL | INHIBITION | ONCOLOGY | REGULATED GENES | GENE-EXPRESSION | DOWN-REGULATION | CELL-GROWTH | IDENTIFICATION | GROWTH IN-VIVO | PROGRESSION | Oligodeoxyribonucleotides, Antisense - pharmacology | Humans | Receptors, Androgen - metabolism | DNA - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Prostatic Neoplasms - genetics | Treatment Failure | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Carcinoma - pathology | Prostatic Neoplasms - drug therapy | Disease Models, Animal | Carcinoma - drug therapy | Prostatic Neoplasms - pathology | DNA - pharmacology | Androgen Antagonists - pharmacology | Oligodeoxyribonucleotides, Antisense - therapeutic use | Down-Regulation - drug effects | Orchiectomy | Xenograft Model Antitumor Assays | Animals | Receptors, Androgen - genetics | Mice, Nude | Androgen Antagonists - therapeutic use | Cell Line, Tumor | Carcinoma - genetics | Mice | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights